Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4 Myeloid 2 Lymphoid 2 Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 266 Lenalidomide 159 daratumumab 137 Bortezomib 114 pomalidomide 91 Calcium Dobesilate 86 Cyclophosphamide 85 carfilzomib 77 Specimen Handling 46 isatuximab 45 fludarabine 43 Biopsy 43 belantamab mafodotin 42 Magnetic Resonance Spectroscopy 38 dexamethasone acetate 34 dexamethasone 21-phosphate 34 auricularum 33 Melphalan 33 talquetamab 29 ixazomib 27 iberdomide 27 fludarabine phosphate 24 selinexor 22 elotuzumab 21 Whole-Body Irradiation 17 X-Rays 15 venetoclax 14 Mycophenolic Acid 13 tocilizumab 12 Stem Cell Transplantation 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

letermovir × Plasma cell × 1 year × Clear all

NCT06920251 2025-12-03

OPTIMUS-EL

Seoul National University Hospital

Phase 2 Recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡